Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Found this:
VIGS REVERSE MERGER PRETTY MUCH CONFIRMED HUGE DD
Cagan McAfee Capital Partners has the SAME ADDRESS AND PHONE# as VIGS
CONTACT
Cagan McAfee Capital Partners, LLC
20400 Stevens Creek Blvd.,
Suite 700
Cupertino, CA 95014
phone: 408-873-0400
http://cmcp.com/index2.html
VISION Global Solutions Inc. VIGS
Contact Info
20400 Stevens Creek Blvd.
Suite 700
Cupertino, CA , 95014
Phone: 408-873-0400
Vigs address via Pinksheets
called Vision Global Solutions Inc. (VIGS) for information with regard to their merger plans but received quite the surprise when the answering machine said “Thank-you for calling Cagan Mcafee Capital Partners.”
Various investors have already indicated through e-mails to us and message board postings, that this may suggest that Cagan Mcafee is the VIGS merger partner and as such, have already adjusted their phone lines to reflect this. So we did some more digging:
-Cagan McAfee Capital Partners has the same address AND phone # as VIGS!
-Eric McAfee (Managing Director of Cagan Mcafee Capital Partners) and Todd Waltz (CEO/Owner of the VIGS shell) BOTH served as management of AEBiofuels.
If this merger candidate possibility does indeed pan out and reign true we are looking at the possibility of a run that will surge well beyond $1 per share quickly!
Cagan McAfee’s partners “have 100 years of cumulative experience operating and investing in growth companies. They have founded eight companies and venture-funded forty businesses, with more than $600 million of direct follow-on financings.”
The companies that the Cagan Mcafee Capital Partners have taken public, have created:
***More than $2 Billion in shareholder value!!!***
Links to Further information regarding Cagan Mcafee Capital Partners Ltd:
http://www.cmcp.com/index2.html
http://www.cmcp.com/management/eric.html
http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=44707398
~Happy Trading
I believe that it has. Look back over the last 3 weeks we had huge volume days. I believe that was GATE buying up the float. IMO of course.
AGEL 10Q
"The Gate Technologies units will be exchanged for the Company’s common stock, each quarter, over a three year period to begin no later the September 30, 2011."
Sounds like a share buy back to me. Could be an interesting 3 years. IMO!
Go AGEL
MM's playing games looking for shares. NITE went to .058 for 15 minutes then back to .06. This is tight. GO VIGS
MM signals:
-100 I need shares.
-200 I need shares badly,but do not take the stock down.
-300 Take the price down so I can load shares
-400 Keep trading it sideways.
-500 Gap the stock. This gap can be either up or down, depending on the direction of the 500 signal.
This is a float lock stock. MM's need shares. Any buys at the ask will move this stock!
Go VIGS!
VIGS
Float locked, should explode any day!
As many of you know, it has been quite a week for us! We are excited to say that Bird Gang Stocks was profiled in the Yahoo business section, about the success of our stock picks and especially coming growth expected from VIGS, which currently has subscribers up more than 297%
The VIGS adventure has only just begun and these current price levels still serve as an excellent opportunity to get involved with this clean shell stock, that is expected to see a reverse merger with a private corporation soon. In accordance to past stated time frames the “current” CEO does not have very much time left on his hands to get this deal completed. Within months his choices are to either complete a reverse merger under his watchful eye, or be ousted as CEO without having been able to complete such a lucrative deal. It reigns clear that his best interest lies in option 1.
Remember that VIGS is trading on the OTCQB, meaning that they adhere to higher standards than many other investment choices within their price range. With that in mind, be on the lookout for filings to be released behind the scenes. There is no telling what such filings may reveal. Perhaps updates just to stay compliant with the trading tier of the OTCQB, or even revelations about merger plans! Keep an eye out ;)
For our newer subscribers (as we have picked up many since the recent press coverage) we would like you to remember that this stock has a VERY small share structure. This means that when shares are purchased at the ask price the price of VIGS rockets upward quickly! If merger news is indeed released we could be looking at a price per share that is 100’s or even thousands of percentage points higher than where it lies even now! As always you have to be in it to win it.
VIGS is definitely one to keep on the radar. We are expecting a significant price explosion with this one.
VIGS
Float locked, should explode any day!
As many of you know, it has been quite a week for us! We are excited to say that Bird Gang Stocks was profiled in the Yahoo business section, about the success of our stock picks and especially coming growth expected from VIGS, which currently has subscribers up more than 297%
The VIGS adventure has only just begun and these current price levels still serve as an excellent opportunity to get involved with this clean shell stock, that is expected to see a reverse merger with a private corporation soon. In accordance to past stated time frames the “current” CEO does not have very much time left on his hands to get this deal completed. Within months his choices are to either complete a reverse merger under his watchful eye, or be ousted as CEO without having been able to complete such a lucrative deal. It reigns clear that his best interest lies in option 1.
Remember that VIGS is trading on the OTCQB, meaning that they adhere to higher standards than many other investment choices within their price range. With that in mind, be on the lookout for filings to be released behind the scenes. There is no telling what such filings may reveal. Perhaps updates just to stay compliant with the trading tier of the OTCQB, or even revelations about merger plans! Keep an eye out ;)
For our newer subscribers (as we have picked up many since the recent press coverage) we would like you to remember that this stock has a VERY small share structure. This means that when shares are purchased at the ask price the price of VIGS rockets upward quickly! If merger news is indeed released we could be looking at a price per share that is 100’s or even thousands of percentage points higher than where it lies even now! As always you have to be in it to win it.
VIGS is definitely one to keep on the radar. We are expecting a significant price explosion with this one.
48K shares just took out the .05's.
L2 shows 60K of .06's then we are at .9.
That's .90 GO VIGS!!
I am still holding 120k, with more powder coming in Monday.
MM signals:
If you see buys of:
100 > I need shares
200 > I need shares badly but dont take it down to get em
300 > Take the price down to get shares....
400 > Trade it sideways based on Supply and Demand
500 > Gap one way or the other, usually to the direction
of the 500 trade. Sometimes -if in the middle -keep the price right where it is
911 > News incoming
Looks like someone is going to get some cheapies early this morning then its back up to 9's ;)
Did you buy at the ASK? AON? there only shows to be 4,807,200 left at he ask between 3 MM's.
L2 shows only 1,719,600 left at 6.
Nite 714600
Doms 5000
Auto 1000000.
Better yet only ETMM with 1,700,000 at 7.
Then we are off to .001
Let's go IKTO.
I figured it out last night! Way to go PIP, good call.
PCIO could fly today!
VIGS up another 40% on float lockdown and R/M pending news.
hey PIP was today's volume 2,918,385? +120.6%
VIGS. I am still holding on to all my VIGS.
VIGS float locked down. Float 7,958,930- Ihubs VIGS board controls 5,189,510 shares of the float! Big players in on this one. R/M news coming.
VIGS float locked down. Float 7,958,930- Ihubs VIGS board controls 5,189,510 shares of the float! Big players in on this one. R/M news coming.
VIGS float locked down. Float 7,958,930- Ihubs VIGS board controls 5,189,510 shares of the float! Big players in on this one. R/M news coming.
Who is selling? The float is locked. If you must sell place you sell orders above bid. Quit giving money away.
I did my part with another 20k at the ask. BTW put me down for 120K total.
lets see it. Hit the ask
I'll sell you my 42M shares at a nickle per share. But I believe that the news out is for a different ANGEL technologies.
I believe this is a different company not our AGEL
http://online.barrons.com/article/PR-CO-20110210-907947.html
Cytomedix Receives CE Mark for Angel and activAT
Quality Manufacturing and Systems Certification to Aid Expansion in Europe
GAITHERSBURG, Md., Feb. 10, 2011 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCBB:CMXI) (the "Company" or "Cytomedix") today announced that the Company has been issued a CE marking certification for its Angel(R) Whole Blood Separation System ("Angel") and its activAT(R) Autologous Thrombin Processing Kit ("activAT"). CE is a mandatory European marking for certain product groups to indicate conformity with the essential health and safety requirements set out in European Directives, and allows Cytomedix to freely sell and distribute its products throughout the 28 countries of the European Economic Area ("EEA").
The receipt of these certifications finalizes the transfer of control over the quality manufacture and distribution of these products in the EEA to Cytomedix in accordance with the terms of the acquisition from the Sorin Group in April 2010.
"With the acquisition of Angel and activAT, we gained an established presence in Europe for our platelet rich plasma products. The receipt of the CE mark allows us to continue to broaden our distribution network and to expand our European footprint," commented Martin P. Rosendale, Chief Executive Officer of Cytomedix.
"This CE mark designation, along with our recent ISO 13485 certification, confirms that Cytomedix has the highest manufacturing standards and systems. We remain committed to upholding these stringent requirements to provide our customers and their patients with the quality they have come to expect from Cytomedix," concluded Mr. Rosendale.
About Cytomedix, Inc.
Cytomedix develops, sells and licenses regenerative biological therapies primarily for wound care, inflammation and angiogenesis. The Company markets the AutoloGel(TM) System, a device for the production of platelet rich plasma ("PRP") gel derived from the patient's own blood for use on a variety of exuding wounds; the Angel(R) Whole Blood Separation System, a blood processing device and disposable products used for the separation of whole blood into red cells, platelet poor plasma ("PPP") and PRP in surgical settings; and the activAT(R) Autologous Thrombin Processing Kit, which produces autologous thrombin serum from PPP. The activAT(R) kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products. The Company is pursuing a multi-faceted strategy to penetrate the chronic wound market with its products, as well as opportunities for the application of AutoloGel(TM) and PRP technology into other markets such as hair transplantation and orthopedics while actively seeking complementary products for the wound care market. Cytomedix also seeks to monetize other product candidates in its pipeline through strategic partnerships, out-licensing or sale. Most notably is its anti-inflammatory peptide (designated CT-112) that has shown promise in preclinical testing. Additional information regarding Cytomedix is available at www.cytomedix.com.
Safe Harbor Statement
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. Such statements contained in this release are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend", and words of similar import, are intended to identify any forward-looking statements. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of CT-112, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital and to continue as a going concern, our ability to execute on our strategy to market the AutoloGel(TM) System as contemplated, our ability to successfully integrate the Angel(R) and activAT(R) product lines into our existing business, to assume and satisfy certain liabilities related to the Angel(R) and activAT(R) product lines, or our ability to service the deferred payments related to the acquisition of the Angel(R) and activAT(R) product lines. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.
CONTACT: Cytomedix, Inc.
David Jorden, Executive Board Member
Martin Rosendale, CEO
Andrew Maslan, CFO
(240) 499-2680
Lippert/Heilshorn & Associates
Anne Marie Fields
(afields@lhai.com)
(212) 838-3777
Bruce Voss
(bvoss@lhai.com)
(310) 691-7100
I believe this is a different company not AGEL
http://online.barrons.com/article/PR-CO-20110210-907947.html
Cytomedix Receives CE Mark for Angel and activAT
Quality Manufacturing and Systems Certification to Aid Expansion in Europe
GAITHERSBURG, Md., Feb. 10, 2011 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCBB:CMXI) (the "Company" or "Cytomedix") today announced that the Company has been issued a CE marking certification for its Angel(R) Whole Blood Separation System ("Angel") and its activAT(R) Autologous Thrombin Processing Kit ("activAT"). CE is a mandatory European marking for certain product groups to indicate conformity with the essential health and safety requirements set out in European Directives, and allows Cytomedix to freely sell and distribute its products throughout the 28 countries of the European Economic Area ("EEA").
The receipt of these certifications finalizes the transfer of control over the quality manufacture and distribution of these products in the EEA to Cytomedix in accordance with the terms of the acquisition from the Sorin Group in April 2010.
"With the acquisition of Angel and activAT, we gained an established presence in Europe for our platelet rich plasma products. The receipt of the CE mark allows us to continue to broaden our distribution network and to expand our European footprint," commented Martin P. Rosendale, Chief Executive Officer of Cytomedix.
"This CE mark designation, along with our recent ISO 13485 certification, confirms that Cytomedix has the highest manufacturing standards and systems. We remain committed to upholding these stringent requirements to provide our customers and their patients with the quality they have come to expect from Cytomedix," concluded Mr. Rosendale.
About Cytomedix, Inc.
Cytomedix develops, sells and licenses regenerative biological therapies primarily for wound care, inflammation and angiogenesis. The Company markets the AutoloGel(TM) System, a device for the production of platelet rich plasma ("PRP") gel derived from the patient's own blood for use on a variety of exuding wounds; the Angel(R) Whole Blood Separation System, a blood processing device and disposable products used for the separation of whole blood into red cells, platelet poor plasma ("PPP") and PRP in surgical settings; and the activAT(R) Autologous Thrombin Processing Kit, which produces autologous thrombin serum from PPP. The activAT(R) kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products. The Company is pursuing a multi-faceted strategy to penetrate the chronic wound market with its products, as well as opportunities for the application of AutoloGel(TM) and PRP technology into other markets such as hair transplantation and orthopedics while actively seeking complementary products for the wound care market. Cytomedix also seeks to monetize other product candidates in its pipeline through strategic partnerships, out-licensing or sale. Most notably is its anti-inflammatory peptide (designated CT-112) that has shown promise in preclinical testing. Additional information regarding Cytomedix is available at www.cytomedix.com.
Safe Harbor Statement
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. Such statements contained in this release are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend", and words of similar import, are intended to identify any forward-looking statements. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of CT-112, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital and to continue as a going concern, our ability to execute on our strategy to market the AutoloGel(TM) System as contemplated, our ability to successfully integrate the Angel(R) and activAT(R) product lines into our existing business, to assume and satisfy certain liabilities related to the Angel(R) and activAT(R) product lines, or our ability to service the deferred payments related to the acquisition of the Angel(R) and activAT(R) product lines. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.
CONTACT: Cytomedix, Inc.
David Jorden, Executive Board Member
Martin Rosendale, CEO
Andrew Maslan, CFO
(240) 499-2680
Lippert/Heilshorn & Associates
Anne Marie Fields
(afields@lhai.com)
(212) 838-3777
Bruce Voss
(bvoss@lhai.com)
(310) 691-7100
http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=100708834.
I believe thatthis is a differnt ANGEL.
http://ih.advfn.com/p.php?pid=trades&symbol=agel.. Loading taking place on AGEL. R/M news could be coming.
Someone is loading the boat with AGEL. 83M voulume ask up to .0002. Gates is going to come through on this one. Huge R/M play
Someone is loading the boat with some AGEL. Hope news will follow!! 83M Ask is at .0002
Once news hits the Bid sitters will be chasing. Get your tickets early for the VIGS run
Thanks! Will do. I didn't know if he has his own site or not. Would like to get in on the next big runner.
How do you get in on Scar's picks? I would like to get in on some of this? Please PM me a contact or details. TIA
I want to know what he has to say. I have been stuck with this too long to get out now.
I have over 5M shares that I have been buying since 4/13/11. I have flipped this once on the 15th @.0023. I have bought back at 14, 11, 11, and 12 and have never been filled completely and never get more than 200K at a time. I have been saying that this is very thin, we just need some MOMO attention on some big boards for this to get some buying volume and this will run. Another 600% in 2 days will be nice. GLTA and watch DIII run!
All we need is for the word to spread and this will fly!! DIII is VERY thin. Patience will pay!
That is how thin this trades.
CNUV now .0064's are falling fast.